Literature DB >> 21690238

Immune activation and suppression by group B streptococcus in a murine model of urinary tract infection.

Kimberly A Kline1, Drew J Schwartz, Warren G Lewis, Scott J Hultgren, Amanda L Lewis.   

Abstract

Group B streptococcus (GBS) is a common commensal of the gastrointestinal and vaginal mucosa and a leading cause of serious infections in newborns, the elderly, and immunocompromised populations. GBS also causes infections of the urinary tract. However, little is known about host responses to GBS urinary tract infection (UTI) or GBS virulence factors that participate in UTI. Here we describe a novel murine model of GBS UTI that may explain some features of GBS urinary tract association in the human host. We observed high titers and heightened histological signs of inflammation and leukocyte recruitment in the GBS-infected kidney. However, extensive inflammation and leukocyte recruitment were not observed in the bladder, suggesting that GBS may suppress bladder inflammation during cystitis. Acute GBS infection induced the localized expression of proinflammatory cytokines interleukin-1α (IL-1α), macrophage inflammatory protein-1α (MIP-1α), MIP-1β, and IL-9, as well as IL-10, more commonly considered an anti-inflammatory cytokine. Using isogenic GBS strains with different capsule structures, we show that capsular sialic acid residues contribute to GBS urinary tract pathogenesis, while high levels of sialic acid O-acetylation attenuate GBS pathogenesis in the setting of UTI, particularly in direct competition experiments. In vitro studies demonstrated that GBS sialic acids participate in the suppression of murine polymorphonuclear leukocyte (PMN) bactericidal activities, in addition to reducing levels of IL-1α, tumor necrosis factor alpha, IL-1β, MIP-1α, and KC produced by PMNs. These studies define several basic molecular and cellular events characterizing GBS UTI in an animal model, showing that GBS participates simultaneously in the activation and suppression of host immune responses in the urinary tract.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21690238      PMCID: PMC3165466          DOI: 10.1128/IAI.00122-11

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  65 in total

1.  Molecular regulation of urothelial renewal and host defenses during infection with uropathogenic Escherichia coli.

Authors:  Indira U Mysorekar; Matthew A Mulvey; Scott J Hultgren; Jeffrey I Gordon
Journal:  J Biol Chem       Date:  2001-12-13       Impact factor: 5.157

2.  MtaR, a regulator of methionine transport, is critical for survival of group B streptococcus in vivo.

Authors:  Daniel Shelver; Lakshmi Rajagopal; Theresa O Harris; Craig E Rubens
Journal:  J Bacteriol       Date:  2003-11       Impact factor: 3.490

3.  Uropathogenic Escherichia coli flagella aid in efficient urinary tract colonization.

Authors:  Kelly J Wright; Patrick C Seed; Scott J Hultgren
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

4.  Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli.

Authors:  M A Mulvey; Y S Lopez-Boado; C L Wilson; R Roth; W C Parks; J Heuser; S J Hultgren
Journal:  Science       Date:  1998-11-20       Impact factor: 47.728

5.  Group B streptococcal capsular sialic acids interact with siglecs (immunoglobulin-like lectins) on human leukocytes.

Authors:  Aaron F Carlin; Amanda L Lewis; Ajit Varki; Victor Nizet
Journal:  J Bacteriol       Date:  2006-09-22       Impact factor: 3.490

6.  The SrtA Sortase of Streptococcus agalactiae is required for cell wall anchoring of proteins containing the LPXTG motif, for adhesion to epithelial cells, and for colonization of the mouse intestine.

Authors:  Lila Lalioui; Elisabeth Pellegrini; Shaynoor Dramsi; Marina Baptista; Nadege Bourgeois; Florence Doucet-Populaire; Christophe Rusniok; Mohamed Zouine; Philippe Glaser; Frank Kunst; Claire Poyart; Patrick Trieu-Cuot
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

7.  Invasive disease due to group B Streptococcus in pregnant women and neonates from diverse population groups.

Authors:  D F Zaleznik; M A Rench; S Hillier; M A Krohn; R Platt; M L Lee; A E Flores; P Ferrieri; C J Baker
Journal:  Clin Infect Dis       Date:  2000-02       Impact factor: 9.079

Review 8.  Group B streptococcal infections in elderly adults.

Authors:  Morven S Edwards; Carol J Baker
Journal:  Clin Infect Dis       Date:  2005-08-16       Impact factor: 9.079

9.  Diversity of group B streptococcus serotypes causing urinary tract infection in adults.

Authors:  Kimberly B Ulett; William H Benjamin; Fenglin Zhuo; Meng Xiao; Fanrong Kong; Gwendolyn L Gilbert; Mark A Schembri; Glen C Ulett
Journal:  J Clin Microbiol       Date:  2009-05-13       Impact factor: 5.948

10.  Molecular mimicry of host sialylated glycans allows a bacterial pathogen to engage neutrophil Siglec-9 and dampen the innate immune response.

Authors:  Aaron F Carlin; Satoshi Uchiyama; Yung-Chi Chang; Amanda L Lewis; Victor Nizet; Ajit Varki
Journal:  Blood       Date:  2009-02-04       Impact factor: 22.113

View more
  27 in total

Review 1.  Host Sialic Acids: A Delicacy for the Pathogen with Discerning Taste.

Authors:  Brandy L Haines-Menges; W Brian Whitaker; J B Lubin; E Fidelma Boyd
Journal:  Microbiol Spectr       Date:  2015-08

2.  Genome-wide mapping of cystitis due to Streptococcus agalactiae and Escherichia coli in mice identifies a unique bladder transcriptome that signifies pathogen-specific antimicrobial defense against urinary tract infection.

Authors:  Chee K Tan; Alison J Carey; Xiangqin Cui; Richard I Webb; Deepak Ipe; Michael Crowley; Allan W Cripps; William H Benjamin; Kimberly B Ulett; Mark A Schembri; Glen C Ulett
Journal:  Infect Immun       Date:  2012-06-25       Impact factor: 3.441

Review 3.  Pathogenesis of Proteus mirabilis Infection.

Authors:  Chelsie E Armbruster; Harry L T Mobley; Melanie M Pearson
Journal:  EcoSal Plus       Date:  2018-02

Review 4.  Urinary tract infections: epidemiology, mechanisms of infection and treatment options.

Authors:  Ana L Flores-Mireles; Jennifer N Walker; Michael Caparon; Scott J Hultgren
Journal:  Nat Rev Microbiol       Date:  2015-04-08       Impact factor: 60.633

5.  Molecular Characterization of Nonhemolytic and Nonpigmented Group B Streptococci Responsible for Human Invasive Infections.

Authors:  Anne Six; Arnaud Firon; Céline Plainvert; Camille Caplain; Abdelouhab Bouaboud; Gérald Touak; Nicolas Dmytruk; Magalie Longo; Franck Letourneur; Agnès Fouet; Patrick Trieu-Cuot; Claire Poyart
Journal:  J Clin Microbiol       Date:  2015-10-21       Impact factor: 5.948

6.  Discovery and characterization of de novo sialic acid biosynthesis in the phylum Fusobacterium.

Authors:  Amanda L Lewis; Lloyd S Robinson; Kavita Agarwal; Warren G Lewis
Journal:  Glycobiology       Date:  2016-09-09       Impact factor: 4.313

7.  Immune modulation by group B Streptococcus influences host susceptibility to urinary tract infection by uropathogenic Escherichia coli.

Authors:  Kimberly A Kline; Drew J Schwartz; Nicole M Gilbert; Scott J Hultgren; Amanda L Lewis
Journal:  Infect Immun       Date:  2012-09-17       Impact factor: 3.441

8.  Enterococcus faecalis Promotes Innate Immune Suppression and Polymicrobial Catheter-Associated Urinary Tract Infection.

Authors:  Brenda Yin Qi Tien; Hwee Mian Sharon Goh; Kelvin Kian Long Chong; Soumili Bhaduri-Tagore; Sarah Holec; Regine Dress; Florent Ginhoux; Molly A Ingersoll; Rohan B H Williams; Kimberly A Kline
Journal:  Infect Immun       Date:  2017-11-17       Impact factor: 3.441

Review 9.  Gram-Positive Uropathogens, Polymicrobial Urinary Tract Infection, and the Emerging Microbiota of the Urinary Tract.

Authors:  Kimberly A Kline; Amanda L Lewis
Journal:  Microbiol Spectr       Date:  2016-04

10.  Group B streptococcus cystitis presenting in a diabetic patient with a massive abdominopelvic abscess: a case report.

Authors:  Kimberly B Ulett; Jennifer H Shuemaker; William H Benjamin; Chee K Tan; Glen C Ulett
Journal:  J Med Case Rep       Date:  2012-08-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.